Treatment Options in the Frontline Setting for Metastatic HER2+ Breast Cancer

Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.